Comparative Pharmacology
Head-to-head clinical analysis: ISOPTO CETAMIDE versus ISOPTO CETAPRED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPTO CETAMIDE versus ISOPTO CETAPRED.
ISOPTO CETAMIDE vs ISOPTO CETAPRED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, disrupting folic acid synthesis and thereby inhibiting bacterial growth.
Combination of sulfonamide antibiotic (sulfacetamide) and corticosteroid (prednisolone). Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene production.
1-2 drops into conjunctival sac every 2-3 hours initially, then taper as infection resolves. Ophthalmic suspension (10% or 30%).
1-2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe cases, may be administered every 1-2 hours until response then gradually taper.
None Documented
None Documented
Terminal elimination half-life of sodium sulfacetamide is 7-12 hours in normal renal function; prolonged in renal impairment.
Sulfacetamide: 7-13 hours (prolonged in renal impairment); Prednisolone: 2.5-3.5 hours (independent of dose). Total duration of anti-inflammatory effect exceeds half-life due to genomic effects.
Primarily renal (sodium sulfacetamide excreted unchanged in urine, ~85% within 24 hours). Minor biliary/fecal elimination.
Renal: sulfacetamide is excreted unchanged in urine (30-40%); prednisolone is metabolized and excreted renally (10-20%) and fecally (30-40%) as conjugates.
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic/Corticosteroid Combination